Financial Reports Latest Updates Industry Maps Economic Calendar

AC Immune SA (ACIU) Annual Reports

Q: Where can I read AC Immune SA (ACIU) annual reports?

Every year on this page links straight to the full text on SEC EDGAR. US annual reports are web pages (HTML) rather than PDFs, so you can read and search them in the browser. 3 filings are currently indexed.

Q: What is the difference between a 10-K and a 20-F?

A 10-K is the annual report of a US domestic issuer; a 20-F is filed by foreign private issuers (Taiwanese companies with US ADRs, such as TSMC, file 20-F). A 40-F applies to Canadian issuers under the MJDS.

AC Immune SA is listed on Nasdaq, classified by the SEC under Pharmaceutical Preparations (SIC 2834). This page indexes 3 annual reports, each linking to the full text on the SEC's EDGAR system.

Company profile

Exchange： Nasdaq
Fiscal year end： 12/31
SEC CIK： 1651625 →

Website：Official site ↗

Financial Highlights

FY2025 Q2 (quarterly, ended 2025-06-30)
	Current	Prior year	YoY
Revenue	0億 CHF	0億 CHF	+90.1%
Operating income	-0億 CHF	-0億 CHF	+7.5%
Net income	-0億 CHF	-0億 CHF	+6.9%

Amounts in CHF.

Source: SEC EDGAR (XBRL company facts)

Financial history

Revenue & profit

Quarterly · In mn (HKD)

Revenue 1.28 mn Net income -30.2 mn

Show table：Income statement

Item	2015Q4	2016Q4	2017Q1	2017Q2	2017Q3	2017Q4	2018Q1	2018Q2	2018Q3	2018Q4	2019Q4	2020Q4	2021Q3	2021Q4	2022Q2	2022Q3	2022Q4	2023Q2	2023Q4	2024Q2	2024Q4	2025Q2	2025Q4
Revenue	39.1	23.2	2.01	0.75	1.07	16.4	1.46	2.03	2.31	1.40	111	15.4	0	0	0	3.93	0	0	14.8	0.69	26.6	1.31	1.28
Operating income	18.6	-10.5	-7.83	-8.25	-9.64	3.19	-11.3	-11.6	-12.2	-14.5	44.5	-61.3	-20.3	-22.8	-19.9	-13.5	-18.7	-17.1	-19.0	-21.0	-11.3	-19.4	-30.6
Net income	20.3	-7.10	-9.45	-12.3	-8.79	4.16	-11.6	-11.1	-13.5	-14.7	45.4	-61.9	-15.9	-21.3	-19.6	-13.5	-18.8	-16.8	-19.9	-22.8	-10.3	-21.2	-30.2

Balance sheet

Quarterly · In mn (HKD)

Total assets 154 mn Total liabilities 109 mn

Equity = assets − liabilities. Balance-sheet figures are period-end balances, not cumulative.

Show table：Balance sheet

Item	2015Q4	2016Q4	2017Q1	2017Q2	2017Q3	2017Q4	2018Q1	2018Q2	2018Q3	2018Q4	2019Q4	2020Q4	2021Q3	2021Q4	2022Q2	2022Q3	2022Q4	2023Q2	2023Q4	2024Q2	2024Q4	2025Q2	2025Q4
Current assets	—	155	—	—	—	130	—	—	—	193	293	232	—	203	—	148	128	99.2	125	181	172	132	96.7
Total assets	—	156	—	—	—	132	—	—	—	197	299	239	—	261	—	206	186	156	183	238	231	190	154
Current liabilities	—	9.92	—	—	—	9.75	—	—	—	13.1	17.5	14.0	—	20.0	—	13.6	11.5	11.2	13.6	101	101	99.0	94.7
Total liabilities	—	13.7	—	—	—	15.2	—	—	—	18.9	26.8	23.3	—	29.5	—	15.5	16.9	16.9	22.2	114	119	115	109
Equity	71.0	142	—	—	—	117	—	—	—	178	272	215	179	232	203	190	169	139	161	123	112	74.7	44.9

Cash flow

Quarterly · In mn (HKD)

Operating -34.9 mn Investing 36.6 mn Financing -0.51 mn

Positive = cash in, negative = cash out.

Show table：Cash flow statement

Item	2015Q4	2016Q4	2017Q1	2017Q2	2017Q3	2017Q4	2018Q1	2018Q2	2018Q3	2018Q4	2019Q4	2020Q4	2021Q3	2021Q4	2022Q2	2022Q3	2022Q4	2023Q2	2023Q4	2024Q2	2024Q4	2025Q2	2025Q4
Operating	44.1	-5.65	—	—	—	-22.1	—	—	—	-44.1	55.2	-59.5	-47.9	-17.8	-42.6	-13.5	-17.4	-30.9	-29.5	74.0	-8.21	-34.4	-34.9
Investing	-0.24	-0.9	—	—	—	-1.84	—	—	—	-32.0	-66.9	28.3	-31.9	-21.7	23.9	-5.12	4.96	37.6	28.0	-99.4	-5.91	26.9	36.6
Financing	27.8	78.8	—	—	—	0.27	—	—	—	109	49.6	-0.8	12.0	28.7	-1.05	-0.14	-0.15	1.77	41.5	-0.75	-0.37	-0.5	-0.51
Cash at period end	76.5	152	—	—	—	124	—	—	—	156	194	161	93.6	82.2	63.1	44.5	31.6	40.0	78.5	51.6	36.3	25.7	26.8

Profitability

Quarterly · %

Operating margin -2393.0% Net margin -2367.2%

Gross, operating and net margin = the respective profit ÷ revenue.

Show table：Profitability

Item	2015Q4	2016Q4	2017Q1	2017Q2	2017Q3	2017Q4	2018Q1	2018Q2	2018Q3	2018Q4	2019Q4	2020Q4	2021Q3	2021Q4	2022Q2	2022Q3	2022Q4	2023Q2	2023Q4	2024Q2	2024Q4	2025Q2	2025Q4
Operating margin	47.6%	-45.0%	-390.5%	-1096.0%	-897.6%	19.4%	-776.5%	-570.5%	-528.0%	-1032.6%	40.1%	-397.0%	—	—	—	-342.2%	-1869700.0%	—	-128.4%	-3051.1%	-42.6%	-1484.5%	-2393.0%
Net margin	51.9%	-30.6%	-471.3%	-1637.0%	-818.7%	25.4%	-796.6%	-549.5%	-586.4%	-1046.2%	40.9%	-401.3%	—	—	—	-343.6%	-1874900.0%	—	-134.4%	-3312.9%	-38.7%	-1622.4%	-2367.2%

Returns & leverage

Quarterly · %

ROE -82.2% ROA -50.1% Debt ratio 70.9%

ROE / ROA = trailing four-quarter net income ÷ average equity / total assets (annual mode: the year’s net income ÷ average of opening and closing). Not computed when the denominator is zero or negative.

Show table：Returns & leverage

Item	2015Q4	2016Q4	2017Q1	2017Q2	2017Q3	2017Q4	2018Q1	2018Q2	2018Q3	2018Q4	2019Q4	2020Q4	2021Q3	2021Q4	2022Q2	2022Q3	2022Q4	2023Q2	2023Q4	2024Q2	2024Q4	2025Q2	2025Q4
ROE	—	—	—	—	—	-20.4%	—	—	—	-34.6%	2.2%	-20.7%	-26.3%	-26.2%	-50.0%	-34.7%	-42.0%	-37.0%	-38.0%	-49.9%	-49.6%	-69.3%	-82.2%
ROA	—	—	—	—	—	-18.3%	—	—	—	-31.0%	2.0%	-18.7%	—	-23.4%	—	-31.7%	-39.4%	-32.9%	-37.7%	-35.3%	-33.5%	-42.8%	-50.1%
Debt ratio	—	8.8%	—	—	—	11.5%	—	—	—	9.6%	9.0%	9.7%	—	11.3%	—	7.5%	9.1%	10.8%	12.1%	48.0%	51.4%	60.7%	70.9%

EPS

Quarterly ·

EPS -0.86

Show table：EPS

Item	2015Q4	2016Q4	2017Q1	2017Q2	2017Q3	2017Q4	2018Q1	2018Q2	2018Q3	2018Q4	2019Q4	2020Q4	2021Q3	2021Q4	2022Q2	2022Q3	2022Q4	2023Q2	2023Q4	2024Q2	2024Q4	2025Q2	2025Q4
EPS（）	0.44	-0.14	-0.17	-0.22	-0.15	0.07	—	—	—	-0.82	0.64	-0.86	—	—	—	—	—	—	—	—	—	—	—

Revenue & profit

Year-to-date · In mn (HKD)

Revenue 7.19 mn Net income -51.0 mn

Year-to-date = summed from the first quarter of the fiscal year; balance-sheet items are period-end balances.

Balance sheet

Year-to-date · In mn (HKD)

Total assets 154 mn Total liabilities 109 mn

Equity = assets − liabilities. Balance-sheet figures are period-end balances, not cumulative.

Profitability

Year-to-date · %

Operating margin -688.8% Net margin -708.2%

Gross, operating and net margin = the respective profit ÷ revenue.

Returns & leverage

Year-to-date · %

ROE -82.2% ROA -50.1% Debt ratio 70.9%

EPS

Year-to-date ·

EPS -0.47

Revenue & profit

Annual · In mn (HKD)

Revenue 7.19 mn Net income -51.0 mn

Annual = sum of four quarters of a complete fiscal year (incomplete years are omitted); balance-sheet items are year-end balances.

Show table：Income statement

Item	2017	2018
Revenue	20.3	7.19
Operating income	-22.5	-49.5
Net income	-26.4	-51.0

Balance sheet

Annual · In mn (HKD)

Total assets 197 mn Total liabilities 18.9 mn

Equity = assets − liabilities. Balance-sheet figures are period-end balances, not cumulative.

Show table：Balance sheet

Item	2017	2018
Current assets	130	193
Total assets	132	197
Current liabilities	9.75	13.1
Total liabilities	15.2	18.9
Equity	117	178

Profitability

Annual · %

Operating margin -688.8% Net margin -708.2%

Gross, operating and net margin = the respective profit ÷ revenue.

Show table：Profitability

Item	2017	2018
Operating margin	-111.3%	-688.8%
Net margin	-130.4%	-708.2%

Returns & leverage

Annual · %

ROE -34.6% ROA -31.0% Debt ratio 9.6%

Show table：Returns & leverage

Item	2017	2018
ROE	-22.6%	-34.6%
ROA	-20.0%	-31.0%
Debt ratio	11.5%	9.6%

EPS

Annual ·

EPS -0.47

Show table：EPS

Item	2017	2018
EPS（）	-0.47	—

Source: SEC EDGAR (XBRL company facts)

Annual reports by year

	20-F
2025	Open full text →
2024	Open full text →
2023	Open full text →

20-F: annual report of a foreign private issuer. Filings are the original documents hosted on SEC EDGAR — this site neither mirrors nor edits them.

FAQ

Where can I read AC Immune SA (ACIU) annual reports?

Every year in the table above links straight to the full text on SEC EDGAR. US annual reports are web pages (HTML) rather than PDFs, so you can read and search them in the browser without downloading anything. 3 filings are currently indexed.

What is the difference between a 10-K and a 20-F?

A 10-K is the annual report of a US domestic issuer, with sections fixed by law: Item 1 Business, Item 1A Risk Factors, Item 7 Management's Discussion and Analysis. A 20-F is filed by foreign private issuers — Taiwanese companies with US ADRs, such as TSMC, file 20-F rather than 10-K. A 40-F applies to Canadian issuers under the MJDS.

Are earnings call materials available here?

No. Earnings calls are not SEC filings, so US pages on this site cover annual reports only. Taiwan has a mandatory investor-conference disclosure regime, and those materials are indexed under Annual Reports.

Source: US Securities and Exchange Commission (SEC) EDGAR. This site indexes public filings and links to them; it hosts no copies, offers no investment advice, and makes no warranty as to timeliness or completeness.
Back to US annual reports, or see the supply-chain maps.